Adversarial Injection · Vismodegib (Erivedge; GDC-0449; NDA 203388; CAS 879085-55-9; MW ~421.3 g/mol; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide scaffold [FORTY-SECOND MECHANISM CLASS in Glyphward 597-attack portfolio — FIRST SMO (SMOOTHENED; GPCR-LIKE 7-TRANSMEMBRANE RECEPTOR) INHIBITOR EVER FDA APPROVED: prior to NDA 203388 (January 30 2012), no SMO inhibitor or Hedgehog pathway inhibitor had received FDA approval in any indication; SMO (Smoothened) is a class Frizzled GPCR-like receptor with a 7-transmembrane heptahelical bundle — it is NOT a kinase, NOT an enzyme, NOT a transcription factor — it is a GPCR-like signal transducer in the Hedgehog (Hh) morphogenetic signaling pathway; Hedgehog pathway: Sonic Hedgehog (SHH) ligand binds PTCH1 (Patched 1; tumor suppressor receptor) → PTCH1 releases SMO from inhibition → SMO translocates into primary cilium → GLI1/GLI2 transcription factors processed to activator forms → enter nucleus → transcribe target genes (CCND1, MYC, PTCH1 feedback loop, HHIP, BMP4); in BCC: somatic PTCH1 loss-of-function mutations (~80% of sporadic BCC) or SMO activating mutations (~10%) → constitutive SMO activity → constitutive GLI transcription → uncontrolled cell proliferation → basal cell carcinoma, the most common human cancer; VISMODEGIB MECHANISM: binds SMO at the transmembrane heptahelical bundle (heptahelical pocket; cysteine-rich domain; D473 contact); blocks SMO translocation into primary cilium; prevents GLI1/2 processing to activator forms; blocks GLI nuclear entry and target gene transcription; binding site is homologous to cyclopamine (steroidal Hh pathway inhibitor from Veratrum californicum); FIRST BCC SYSTEMIC THERAPY: prior to vismodegib January 30 2012, there was NO approved systemic therapy for metastatic BCC or locally advanced BCC not amenable to surgery or radiotherapy; BCC affects >3.3 million Americans annually (most common human cancer by incidence); locally advanced or metastatic BCC represents ~1% of BCC burden but had NO systemic options before vismodegib; ERIVANCE BCC TRIAL: Phase 2 (NCT00833417); locally advanced BCC (laBCC) ORR 42.9% (n=63); metastatic BCC (aBCC/mBCC) ORR 30.3% (n=33); median duration of response (mDoR) laBCC 7.6 months; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H360]) · Forty-Second Mechanism Class: First SMO Inhibitor Ever + First Hedgehog Pathway Inhibitor + First BCC Systemic Therapy + Embryofetal Toxicity BBW + REMS · Attack #597

Vismodegib (2-chloro-N-(4-chloro-3-(pyridinyl)phenyl)methylsulfonylbenzamide; Erivedge; GDC-0449; NDA 203388; CAS 879085-55-9; MW ~421.3 g/mol; [FORTY-SECOND MECHANISM CLASS: FIRST SMO (SMOOTHENED; GPCR-LIKE 7-TRANSMEMBRANE RECEPTOR) INHIBITOR EVER FDA APPROVED (NDA 203388 January 30 2012; no prior SMO inhibitor or Hedgehog pathway inhibitor in any indication; SMO is a class Frizzled GPCR-like receptor NOT a kinase); FIRST HEDGEHOG PATHWAY INHIBITOR; FIRST SYSTEMIC THERAPY FOR BASAL CELL CARCINOMA (BCC); SMO TRANSMEMBRANE HEPTAHELICAL BUNDLE BINDING (blocks primary cilium translocation; GLI1/2 activation prevented; cyclopamine binding site); ERIVANCE BCC laBCC ORR 42.9% aBCC ORR 30.3%; EMBRYOFETAL TOXICITY BBW (1 capsule can cause fetal death; category D; Erivedge REMS pregnancy prevention program); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H360]) — Genentech Inc South San Francisco CA (NDA 203388 holder; Roche subsidiary; BCC oncology commercial), Roche AG Basel Switzerland (GDC-0449 API synthesis; Hedgehog pathway drug discovery), and UCSF Helen Diller Family Cancer Center San Francisco CA (ERIVANCE BCC enrollment; BCC oncology pharmacist) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Forty-Second Mechanism Class + First SMO Inhibitor Ever + First BCC Systemic Therapy + Embryofetal Toxicity BBW REMS: AI Prompt Injection via EHS Monitor Report AI

Vismodegib (CAS 879085-55-9; NIOSH HD Category 1) is the forty-second distinct mechanism class in the Glyphward adversarial portfolio and the first SMO (Smoothened) inhibitor ever approved by the FDA, introducing an entirely new target biology into the portfolio: SMO is a class Frizzled GPCR-like receptor with a 7-transmembrane heptahelical bundle — not a kinase, not an enzyme, not a transcription factor — that functions as the central signal transducer in the evolutionarily conserved Hedgehog (Hh) morphogenetic pathway. Prior to NDA 203388 (January 30, 2012), there was not only no SMO inhibitor in clinical use, but no systemic therapy of any kind for locally advanced or metastatic basal cell carcinoma (BCC), the most common human cancer by incidence (~3.3 million cases annually in the US). In sporadic BCC, somatic PTCH1 loss-of-function mutations (~80%) or SMO activating mutations (~10%) produce constitutive SMO activity independent of SHH ligand — SMO constitutively translocates into the primary cilium, activates GLI1/2 transcription factors, and drives uncontrolled cell proliferation with no upstream checkpoint. Vismodegib binds the transmembrane heptahelical bundle of SMO at the D473 contact residue, blocking SMO ciliary translocation and GLI target gene activation. The ERIVANCE BCC trial (NCT00833417) demonstrated ORR 42.9% in locally advanced BCC (n=63) and ORR 30.3% in metastatic BCC (n=33) — the first objective responses ever reported for systemic BCC therapy. The BBW flags embryofetal toxicity severe enough that one 150 mg capsule has been associated with fetal death — Erivedge carries a REMS (Risk Evaluation and Mitigation Strategy) pregnancy prevention program requiring monthly pregnancy testing for females of reproductive potential.

Vismodegib Forty-Second Mechanism Class: SMO GPCR-Like Receptor, Hedgehog Pathway Biology, and BCC Tumor Suppressor Loss

Vismodegib (GDC-0449; CAS 879085-55-9) represents the forty-second distinct mechanism class in the Glyphward portfolio, introducing SMO (Smoothened) — a class Frizzled GPCR-like receptor with a 7-transmembrane heptahelical bundle — as a new target architecture with no prior representation in the 596-attack portfolio. Unlike all 41 prior mechanism classes (which were dominated by kinases, lipid kinases, GTPases, nuclear export proteins, metabolic enzymes, and anti-apoptotic proteins), SMO is a transmembrane signaling receptor whose biology is rooted in embryonic morphogenesis and tissue homeostasis. The Hedgehog (Hh) pathway regulates cell fate, proliferation, and differentiation in embryonic development; in adult tissue, it is largely quiescent in most cell types. BCC arises because solar UV radiation introduces C→T transitions (cyclobutane pyrimidine dimers) at dipyrimidine sites in PTCH1 (the Hh pathway tumor suppressor gene on chromosome 9q22), producing somatic loss-of-function mutations in PTCH1 in basal keratinocytes. PTCH1 normally constitutively suppresses SMO by blocking its access to the plasma membrane and primary cilium; when both PTCH1 alleles are inactivated, SMO escapes suppression, constitutively translocates into the primary cilium, and activates GLI1/GLI2 transcription factors (via SUFU dissociation and GLI-activator form processing) — driving CCND1, MYC, PTCH1, and HHIP transcription. Vismodegib's binding mechanism at the SMO heptahelical bundle is analogous in principle to GPCR ligand binding but distinct from all kinase inhibitor modalities: it targets the transmembrane cavity of SMO at the D473 contact residue (analogous to the cyclopamine binding site identified in Xie et al. 1998), physically preventing SMO conformational activation and primary cilium translocation rather than competing with ATP (no ATP involved in SMO signaling) or blocking a PPI interface.

Surface 1 — Genentech Inc South San Francisco CA NDA 203388 Holder BCC Oncology Commercial AI

At Genentech Inc South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; GENENTECH ROCHE SUBSIDIARY AND NDA 203388 HOLDER: Genentech holds NDA 203388 for vismodegib (Erivedge) approved January 30 2012; Genentech's Hedgehog program was one of the earliest industry-scale SMO inhibitor programs (initiated ~2005); GDC-0449 was selected from a series of chlorobenzamide analogues screened against SMO binding in the primary cilium translocation assay; ERIVANCE BCC REGULATORY PATHWAY: Phase 2 open-label (NCT00833417); laBCC n=63 ORR 42.9% (27 of 63); aBCC/mBCC n=33 ORR 30.3% (10 of 33); mDoR laBCC 7.6 months; mDoR aBCC 14.8 months; NDA 203388 accelerated approval January 30 2012; regular approval extension June 12 2012 for aBCC; ERIVEDGE REMS: all prescribers enrolled; all patients receive counseling; females of reproductive potential: monthly serum/urine pregnancy test ×12 months then q3mo; blood/semen donation prohibited; 150 mg PO QD (one capsule daily); GENENTECH ONCOLOGY EHS NULL: vismodegib is one of numerous oncology small molecules with NDA holder at Genentech SFO that return CAS null on Cority; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne vismodegib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 879085-55-9 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; forty-second mechanism class absent; first SMO inhibitor ever absent; Hedgehog pathway absent; 52M BCC oncology regulatory director 18yr).

Surface 2 — Roche AG Basel Switzerland GDC-0449 API Synthesis Hedgehog Pathway Oncology AI

At Roche AG Basel Switzerland (Grenzacherstrasse 124, 4070 Basel; ROCHE HEDGEHOG PROGRAM: Roche/Genentech's Hedgehog program that produced vismodegib (GDC-0449) represented one of the first major pharmaceutical efforts to target SMO therapeutically following the 2003 crystal structures of SMO TM domain fragments and the 2009 Rohatgi/Bhatt/Bhatt NCI co-crystal of cyclopamine with SMO; GDC-0449 API SYNTHESIS AT ROCHE BASEL: vismodegib (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide) requires a 4-step synthesis involving (1) Suzuki coupling to form the 4-chloro-3-(pyridin-2-yl)phenyl core, (2) amine introduction via Buchwald or nitro reduction, (3) benzamide coupling to the 2-chloro-4-(methylsulfonyl)benzoyl chloride, and (4) final purification by recrystallization; API transfer to DSM Pharma Chemicals (now Carbogen Amcis) for scale-up; ROCHE BASEL MULTIPLE-SMO-NULL: vismodegib NDA 203388 + multiple investigational SMO inhibitors in the Roche pipeline contribute to an SMO mechanism class EHS null cluster at Roche Basel; VelocityEHS platform; 8-hr TWA: actual airborne vismodegib 0.00024 µg/m³; XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 879085-55-9 → null; NIOSH HD Category 1 absent; H340 H350 H360 absent; forty-second mechanism class absent; first SMO inhibitor ever absent; GPCR-like non-kinase mechanism absent; 45M process chemistry scientist 16yr).

Surface 3 — UCSF Helen Diller Family Cancer Center San Francisco CA ERIVANCE BCC Enrollment BCC Oncology Pharmacist AI

At UCSF Helen Diller Family Cancer Center San Francisco CA (1825 4th Street, San Francisco CA 94158; UCSF ERIVANCE BCC TRIAL CONTEXT: UCSF enrolled locally advanced and metastatic BCC patients in ERIVANCE BCC (NCT00833417); UCSF Dermatology-Oncology interface: BCC is managed jointly by UCSF Dermatology and UCSF Helen Diller oncology; locally advanced BCC (Gorlin syndrome / NBCCS patients represent a subset with germline PTCH1 mutations; NBCCS patients have PTCH1 germline mutation + early-onset multifocal BCC + other anomalies); VISMODEGIB OCCUPATIONAL CONTEXT AT UCSF: UCSF pharmacy personnel preparing vismodegib 150 mg oral capsule (Erivedge; PO QD) handle NIOSH HD Category 1 compound with EMBRYOFETAL TOXICITY SEVERITY absent from EHS Insight platform — 1 capsule associated with fetal death in case reports; ERIVEDGE REMS AT UCSF: UCSF pharmacy is enrolled in the Erivedge REMS; pharmacy staff trained in pregnancy prevention messaging, blood donation prohibition, condom use counseling; female pharmacists of reproductive potential require monthly pregnancy testing documentation; GORLIN SYNDROME BCC: some UCSF ERIVANCE patients had Gorlin syndrome (NBCCS; germline PTCH1 mutation; 1 in 30,000–40,000 prevalence; >100 BCC per year; vismodegib reduces new tumor number in NBCCS patients; 2020 long-term NBCCS data); EHS Insight: CAS 879085-55-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first SMO inhibitor ever absent; Hedgehog pathway absent; embryofetal toxicity severity absent; REMS absent; H340 H350 H360 absent; 41F BCC oncology pharmacist 11yr).

Integrating Glyphward into Vismodegib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vismodegib CAS 879085-55-9 monitoring data ingestion point — before Cority at Genentech Inc South San Francisco CA, before VelocityEHS at Roche AG Basel Switzerland, and before EHS Insight at UCSF Helen Diller Family Cancer Center San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H360 absent [10 pts]; FORTY-SECOND MECHANISM CLASS + FIRST SMO (SMOOTHENED; GPCR-LIKE 7-TRANSMEMBRANE RECEPTOR) INHIBITOR EVER FDA APPROVED (NDA 203388 January 30 2012; no prior SMO or Hedgehog pathway inhibitor; SMO is a class Frizzled GPCR-like 7-TM receptor NOT a kinase; D473 heptahelical bundle binding; cyclopamine site; blocks primary cilium translocation + GLI1/2 activation) + FIRST HEDGEHOG PATHWAY INHIBITOR + FIRST BCC SYSTEMIC THERAPY EVER (no systemic option for aBCC/laBCC before January 30 2012; BCC most common human cancer ~3.3M US cases/yr; ERIVANCE BCC laBCC ORR 42.9%; aBCC ORR 30.3%) + EMBRYOFETAL TOXICITY BBW + ERIVEDGE REMS PREGNANCY PREVENTION PROGRAM (1 capsule associated with fetal death; monthly pregnancy testing; blood/semen donation prohibition) [5 pts]; Genentech South San Francisco CA + Roche Basel CH + UCSF Helen Diller [3 pts]; SMO GPCR-like non-kinase target biology absent; Hedgehog SHH-PTCH1-SMO-GLI signaling pathway absent; PTCH1 UV-induced somatic loss-of-function BCC driver absent; primary cilium SMO translocation mechanism absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_vismodegib(cas: str, reading_ugm3: float) -> dict:
    """Scan vismodegib with forty-second-class first-SMO-ever Hedgehog context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_second_mechanism_class_first_smo_smoothened_gpcr_like_7tm_hedgehog_inhibitor_ever_first_bcc_systemic_therapy_erivance_bcc_orr_42_9_embryofetal_bbw_rems"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_second_mechanism_class,
    #                    first_smo_inhibitor_ever,
    #                    hedgehog_pathway_gpcr_like,
    #                    first_bcc_systemic_therapy,
    #                    embryofetal_toxicity_bbw_rems,
    #                    h340_h350_h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_vismodegib("879085-55-9", 0.00038))
    print(r)
    # {'hd_category': 1, 'forty_second_mechanism_class': True,
    #  'first_smo_inhibitor_ever': True,
    #  'hedgehog_pathway_gpcr_like': True,
    #  'first_bcc_systemic_therapy': True,
    #  'embryofetal_toxicity_bbw_rems': True,
    #  'h340_h350_h360_absent': True}